Igc Pharma Inc Quick Ratio (IGC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Igc Pharma Inc   (NYSEAMER: IGC)

Igc Pharma Inc 's Quick Ratio

IGC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Igc Pharma Inc 's Cash & cash equivalent grew by 50.64 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Igc Pharma Inc 's Quick Ratio to 0.11, Quick Ratio remained below Igc Pharma Inc average.

Within Major Pharmaceutical Preparations industry 419 other companies have achieved higher Quick Ratio than Igc Pharma Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3455 to 3635.

Explain Quick Ratio?
How much Cash & cash equivalents IGC´s has?
What are IGC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IGC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4
Y / Y Current Liabilities Change 90.55 % 27.29 % -3.67 % -45.97 % -30.7 %
Y / Y Cash & cash equivalent Change -22.03 % -41.98 % -66.19 % -26.91 % -75.11 %
Quick Ratio MRQ 0.11 0.08 0.18 0.75 0.26
IGC's Total Ranking # 3635 # 3455 # 1919 # 2404 #
Seq. Current Liabilities Change 14.41 % 27.29 % 49.08 % -12.23 % -23.57 %
Seq. Cash & cash equivalent Change 50.64 % -41.98 % -64.16 % 148.9 % 12.1 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 420
Healthcare Sector # 842
Overall Market # 3635


Quick Ratio Statistics
High Average Low
29.17 2.91 0.08
(Dec 31 2019)   (Mar 31 2026)




Financial Statements
Igc Pharma Inc 's Current Liabilities $ 3 Millions Visit IGC's Balance sheet
Igc Pharma Inc 's Cash & cash equivalent $ 0 Millions Visit IGC's Balance sheet
Source of IGC's Sales Visit IGC's Sales by Geography


Cumulative Igc Pharma Inc 's Quick Ratio

IGC's Quick Ratio for the trailling 12 Months

IGC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 8.81 % -15.39 % -22.29 % -17.76 % 3.29 %
Y / Y Cash & cash equivalent TTM Growth -41.05 % -55.28 % -58.48 % -59.75 % -62.06 %
Quick Ratio TTM 0.21 0.27 0.31 0.41 0.39
Total Ranking TTM # 4172 # 3182 # 3292 # 3060 #
Seq. Current Liabilities TTM Growth 18.66 % 7.95 % -1.1 % -14.11 % -7.72 %
Seq. Cash & cash equivalent TTM Growth -4.5 % -7.1 % -24.88 % -11.55 % -27.55 %

Quick ratio ranking by company, industry and sector >> Back to IGC Financial Strength Comparisons >> Go to Compare IGC Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $3.29 millions, cumulative Quick Ratio decreased to 0.21 below the Igc Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Igc Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3182 to 4172.

Explain Quick Ratio?
How much Cash & cash equivalents IGC´s has?
What are IGC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 445
Healthcare Sector # 916
Within the Market # 4172


trailing twelve months Quick Ratio Statistics
High Average Low
20.62 2.71 0.14
(Dec 31 2019)   (Dec 31 2012)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Ainos Inc   0.29 $ 1.423  Millions$ 4.928  Millions
Elanco Animal Health Incorporated  0.29 $ 530.000  Millions$ 1,852.000  Millions
Provectus Biopharmaceuticals Inc   0.27 $ 1.157  Millions$ 4.234  Millions
Vireo Growth Inc.  0.27 $ 104.100  Millions$ 390.700  Millions
Phibro Animal Health Corporation  0.26 $ 81.994  Millions$ 316.468  Millions
Merck and Co Inc   0.26 $ 7,141.000  Millions$ 27,731.000  Millions
Indivior Pharmaceuticals Inc   0.26 $ 222.000  Millions$ 868.000  Millions
Propanc Biopharma Inc   0.25 $ 0.832  Millions$ 3.354  Millions
Teva Pharmaceutical Industries Limited  0.23 $ 3,655.000  Millions$ 15,646.000  Millions
Cytodyn inc   0.22 $ 11.852  Millions$ 53.727  Millions
Collegium Pharmaceutical Inc   0.22 $ 129.467  Millions$ 589.861  Millions
International Stem Cell Corporation  0.22 $ 1.089  Millions$ 4.984  Millions
Earth Science Tech Inc   0.22 $ 0.631  Millions$ 2.902  Millions
Viatris Inc   0.22 $ 1,368.700  Millions$ 6,345.800  Millions
Eli Lilly And Company  0.19 $ 8,950.000  Millions$ 47,741.000  Millions
Polomar Health Services, Inc.  0.18 $ 0.188  Millions$ 1.063  Millions
Tempest Therapeutics Inc   0.18 $ 0.779  Millions$ 4.450  Millions
Abbvie Inc   0.16 $ 6,569.000  Millions$ 41,642.000  Millions
Amneal Pharmaceuticals Inc   0.15 $ 136.280  Millions$ 883.187  Millions
Neonc Technologies Holdings Inc   0.15 $ 3.573  Millions$ 23.507  Millions
Jaguar Health Inc   0.15 $ 3.788  Millions$ 25.380  Millions
Alaunos Therapeutics Inc   0.14 $ 0.124  Millions$ 0.864  Millions
Cumberland Pharmaceuticals Inc   0.11 $ 3.862  Millions$ 35.193  Millions
Igc Pharma Inc   0.11 $ 0.354  Millions$ 3.287  Millions
Tuhura Biosciences Inc   0.11 $ 0.996  Millions$ 9.255  Millions
Gridai Technologies Corp  0.10 $ 1.380  Millions$ 14.146  Millions
Bioxcel Therapeutics Inc   0.09 $ 12.841  Millions$ 137.149  Millions
Galectin Therapeutics Inc   0.09 $ 13.275  Millions$ 151.619  Millions
Lftd Partners Inc   0.08 $ 0.304  Millions$ 3.648  Millions
Processa Pharmaceuticals Inc   0.08 $ 0.196  Millions$ 2.387  Millions

Date modified: 2026-08-16T08:24:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.